Through our blog, we hope to create a community where we can support and challenge each other through conversations, discussions and storytelling, and work together to move the field of oncology forward.

  • Shifting the Treatment Paradigm in Blood Cancers: New Insights

    For decades, the approach to treating diseases like acute leukemia, lymphoma, and myeloma was based on assigning patients to prognostic groups and making uniform treatment decisions within that group. But with comprehensive genomic profiling, we can begin to unravel the heterogeneity within each group and develop more …

    Continue Reading

  • Personalized: Lung cancer’s present offers a glimpse at cancer’s future

    The impact of precision medicine on cancer treatment becomes more apparent each day. If you consider the patient experience, you start to see how much has changed already — and how much more is possible. When I began caring for patients with non-small cell lung cancer (NSCLC) about 30 years ago, the major therapeutic …

    Continue Reading

  • Expanding options for more patients: Introducing FoundationOne®Liquid

    With a single tissue biopsy and comprehensive genomic profiling (CGP), people diagnosed with cancer have access to more information about their disease than ever before. These insights are rapidly advancing precision medicine and giving patients the chance to find the treatment most likely to benefit their specific …

    Continue Reading

  • Setting the Pace for Blood Tumor Mutational Burden

    New biomarkers for cancer immunotherapy have taken center stage at major oncology meetings recently, mostly notably the genomic biomarker tumor mutational burden (TMB). Multiple clinical trial results support TMB’s potential in identifying patients most likely to benefit from immunotherapy across a wide range of tumor …

    Continue Reading

  • Approximately 15 percent of all colorectal cancers (CRCs) are genetically defined as microsatellite instability (MSI) high.1 This means that the DNA repair mechanisms in the tumor cells are faulty, and as a result, they can acquire a significant number of mutations that can make them easily recognizable by the immune …

    Continue Reading

  • Quantum Leaps for Quantitative Markers

    Recent clinical data demonstrate the enormous impact that quantitative genomic biomarkers like tumor mutational burden (TMB) have made on the treatment landscape, especially in immunotherapy. TMB was a major topic at the recent American Association for Cancer Research (AACR) Annual Meeting, standing alongside data …

    Continue Reading

  • The Future of Personalized Cancer Care is Now

    Cancer immunotherapy has revolutionized how we view cancer treatment. When it works, the results are transformative. But right now, only a subset of people treated with immunotherapies respond. The ability to reliably identify both responders and non-responders to immunotherapy is one of the most important …

    Continue Reading

  • FoundationOne CDx™ is the first FDA-approved comprehensive genomic profiling assay and broad companion diagnostic for solid tumors. Find out how FoundationOne CDx can provide a broad range of biological insights and advantages. …

    Continue Reading

  • The Clinical Value of a Comprehensive Approach to Companion Diagnostics

    Genomic biomarkers have redefined how we treat cancer. By revealing the unique features of each person’s tumor, biomarkers often allow physicians to select highly specific therapies that are most likely to benefit their patients. As such, companion diagnostics that measure these biomarkers have become essential …

    Continue Reading

  • Informing Precision Treatment Approaches for Breast Cancer

    Breast cancer is an important example of how a better understanding of cancer biology can lead to more personalized and precise treatments that improve patient care and prognosis. Surgery, hormone therapy, and chemotherapy were the standard of care for decades, but research into the HER2 gene as a potential …

    Continue Reading